Immunology

Remission that holds after treatment stops is no longer a hypothetical. This edition opens with a review defining what disease modification in atopic dermatitis would actually require, then looks at what the evidence shows so far: sustained benefit in patients over 60, whether treating children early can change where the atopic march ends, and what happens to skin nerves and barrier proteins after 16 weeks of treatment.

Diagnostic uncertainty remains a common challenge in patients presenting with chronic respiratory symptoms. Watch this on-demand expert session featuring Prof Peter Wark as he discusses practical approaches to distinguishing asthma from COPD, recognizing overlapping features, and identifying patients who may benefit from early specialist referral. 

Access ERS 2026 Congress highlights on severe asthma, COPD, and biologic therapies. Real-world evidence and clinical insights for HCPs

In this issue, we feature three studies that provide insights into disease modification in atopic dermatitis, examining microbiome restoration, long-term infection outcomes in real-world practice, and clinical responses in erythrodermic presentations.

Missed this webinar? You can now watch the recording of the webinar to learn about the role of biologics in severe asthma and COPD through real-world clinical cases presented by a panel of expert clinicians.

Curated evidence on atopic dermatitis, organised around the four disease-modification pillars — starting with new data on skin-barrier restoration in children.

Curated June evidence on atopic dermatitis, organised around the four disease-modification pillars — starting with new data on skin-barrier restoration in children